Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 3/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556458 | 1.00 | MPO (0.44) | MPOLOXL2DPP4IDO1AGXT | |
| Hydrochloric Acid SCHEMBL14157220 | 0.98 | MPO (0.43) | MPOLOXL2DPP4IDO1AGXT | |
| SCHEMBL30814757 | 0.83 | TAAR1 (0.52) | MPODPP4IDO1AGXTTAAR1 | |
| SCHEMBL535214 | 0.83 | TAAR1 (0.52) | MPODPP4IDO1AGXTTAAR1 | |
| SCHEMBL3910128 | 0.82 | MPO (0.44) | MPOLOXL2DPP4IDO1AGXT | |
| Hydrochloric Acid SCHEMBL18524413 | 0.81 | TAAR1 (0.50) | MPODPP4IDO1AGXTTAAR1 | |
| Hydrochloric Acid SCHEMBL856646 | 0.80 | MPO (0.43) | MPOLOXL2DPP4IDO1AGXT | |
| SCHEMBL31021710 | 0.79 | DPP4 (0.37) | DPP4IDO1AGXTALDH1A1HTR2A | |
| SCHEMBL156831 | 0.79 | DPP4 (0.37) | DPP4IDO1AGXTALDH1A1HTR2A | |
| SCHEMBL29374861 | 0.79 | DPP4 (0.37) | DPP4IDO1AGXTALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568399-B1 | AZIRIDINE SPINOSYN DERIVATIVES AND METHODS OF MAKING | AGRIMETIS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-12391695-B2 | PRMT5 inhibitors | LUPIN LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| EP-4536660-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240083888-A1 | SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF | REISTONE BIOPHARMA COMPANY LIMITED (CN) | 2024-03-14 | — | — | US | disclosed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2023238065-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-1671391-A | Novel methods and compositions for pain relief | ALLERGAN INC (US) | 2005-09-21 | — | — | CN | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1507536-A2 | COMPOSITIONS AND THEIR USES FOR ALLEVIATING PAIN | ALLERGAN, INC. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040132824-A1 | Novel methods and compositions for alleviating pain | ALLERGAN, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20030229088-A1 | Novel methods and compositions for alleviating pain | ALLERGAN, INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003099289-A2 | COMPOSITIONS AND THEIR USES FOR ALLEVIATING PAIN | ALLERGAN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099289-A2 | COMPOSITIONS AND THEIR USES FOR ALLEVIATING PAIN | ALLERGAN, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391695-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | MPO 1795/4885LOXL2 3592/4885DPP4 1358/4885 |
| US-20030229088-A1 | Novel methods and compositions for alleviating pain | ADRA2A, ADRB2, ADRA2B | MPO 1775/4885LOXL2 1226/4885DPP4 3315/4885 |
| US-20040132824-A1 | Novel methods and compositions for alleviating pain | ADRA2A, ADRB2, ADRA2B | MPO 1775/4885LOXL2 1226/4885DPP4 3315/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | MPO 1521/4885LOXL2 4662/4885DPP4 2805/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | MPO 3804/4885LOXL2 2790/4885DPP4 1036/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | MPO 2900/4885LOXL2 3329/4885DPP4 3718/4885 |
| US-20240083888-A1 | SMALL MOLECULE INHIBITOR FOR CATHEPSIN C AND MEDICINAL USE THEREOF | CTSF, CTSV, CTSB | MPO 55/4885LOXL2 2340/4885DPP4 442/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | MPO 3804/4885LOXL2 2790/4885DPP4 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.